Oklo stock tumbles as Financial Times scrutinizes valuation
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Chief Financial Officer Steven P. Coen sold 1,312 shares of Class A Common Stock on October 17, 2025, at a price of $13.649, totaling $17907. The transaction comes as DNA shares show significant momentum, with an 80% surge over the past six months. According to InvestingPro analysis, the stock currently appears undervalued compared to its Fair Value.
On October 16, 2025, Coen also acquired a total of 2,547 shares of Class A Common Stock through the exercise of restricted stock units. With the company’s next earnings report due on November 7, investors can access comprehensive analysis and 10+ additional ProTips through InvestingPro’s detailed research reports.
In other recent news, Ginkgo Bioworks Holdings reported a significant miss in its Q2 2025 earnings, with earnings per share (EPS) at -1.1 compared to the forecast of -0.1. The company’s revenue also fell short of expectations, coming in at $49.6 million against a projected $86.73 million. These earnings and revenue results have attracted attention from investors and analysts alike. Additionally, Ginkgo Bioworks announced that the United States District Court for the Northern District of California granted preliminary approval for a proposed settlement to resolve multiple stockholder derivative actions. This settlement agreement, initially reached in May 2025, involves lawsuits filed on behalf of the company against certain individual defendants. The court has required Ginkgo Bioworks to notify stockholders about the settlement, with a final hearing scheduled for December 18, 2025. These developments mark significant recent events for Ginkgo Bioworks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.